Thomas A Anyorigiya1,2,3, Sandra Castel1, Katya Mauff4, Frank Atuguba3,5, Bernhards Ogutu6, Abraham Oduro3, David Dosoo7, Kwaku-Poku Asante7, Seth Owusu-Agyei8, Alexander Dodoo9, Abraham Hodgson3,10, Fred Binka8, Lesley J Workman1,2, Elizabeth N Allen1,2, Paolo Denti1,2, Lubbe Wiesner1,2, Karen I Barnes11,12. 1. Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa. 2. UCT/MRC Collaborating Centre for Optimising Antimalarial Therapy (CCOAT), University of Cape Town, Cape Town, South Africa. 3. Navrongo Health Research Centre, Navrongo, Ghana. 4. Department of Statistical Sciences, University of Cape Town, Cape Town, South Africa. 5. Dodowa Health Research Centre, Dodowa, Ghana. 6. Centre for Clinical Research, Kenya Medical Research Institute, Nairobi, Kenya. 7. Kintampo Health Research Centre, Kintampo, Ghana. 8. University for Health and Allied Sciences, Ho, Volta Region, Ghana. 9. Ghana Standards Authority, Accra, Ghana. 10. Research and Development Division, Ghana Health Service, Accra, Ghana. 11. Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa. karen.barnes@uct.ac.za. 12. UCT/MRC Collaborating Centre for Optimising Antimalarial Therapy (CCOAT), University of Cape Town, Cape Town, South Africa. karen.barnes@uct.ac.za.
Abstract
BACKGROUND: Accurate measurement of anti-malarial drug concentrations in therapeutic efficacy studies is essential to distinguish between inadequate drug exposure and anti-malarial drug resistance, and to inform optimal anti-malarial dosing in key target population groups. METHODS: A sensitive and selective LC-MS/MS method was developed and validated for the simultaneous determination of amodiaquine and its active metabolite, desethylamodiaquine, and used to describe their pharmacokinetic parameters in Ghanaian patients with uncomplicated falciparum malaria treated with the fixed-dose combination, artesunate-amodiaquine. RESULTS: The day-28 genotype-adjusted adequate clinical and parasitological response rate in 308 patients studied was > 97% by both intention-to-treat and per-protocol analysis. After excluding 64 patients with quantifiable amodiaquine concentrations pre-treatment and 17 with too few quantifiable concentrations, the pharmacokinetic analysis included 227 patients (9 infants, 127 aged 1-4 years, 91 aged ≥ 5 years). Increased median day-3 amodiaquine concentrations were associated with a lower risk of treatment failure [HR 0.87 (95% CI 0.78-0.98), p = 0.021]. Amodiaquine exposure (median AUC0-∞) was significantly higher in infants (4201 ng h/mL) and children aged 1-5 years (1994 ng h/mL) compared to older children and adults (875 ng h/mL, p = 0.001), even though infants received a lower mg/kg amodiaquine dose (median 25.3 versus 33.8 mg/kg in older patients). Desethylamodiaquine AUC0-∞ was not significantly associated with age. No significant safety concerns were identified. CONCLUSIONS: Efficacy of artesunate-amodiaquine at currently recommended dosage regimens was high across all age groups. Reassuringly, amodiaquine and desethylamodiaquine exposure was not reduced in underweight-for-age young children or those with high parasitaemia, two of the most vulnerable target populations. A larger pharmacokinetic study with close monitoring of safety, including full blood counts and liver function tests, is needed to confirm the higher amodiaquine exposure in infants, understand any safety implications and assess whether dose optimization in this vulnerable, understudied population is needed.
BACKGROUND: Accurate measurement of anti-malarial drug concentrations in therapeutic efficacy studies is essential to distinguish between inadequate drug exposure and anti-malarial drug resistance, and to inform optimal anti-malarial dosing in key target population groups. METHODS: A sensitive and selective LC-MS/MS method was developed and validated for the simultaneous determination of amodiaquine and its active metabolite, desethylamodiaquine, and used to describe their pharmacokinetic parameters in Ghanaian patients with uncomplicated falciparum malaria treated with the fixed-dose combination, artesunate-amodiaquine. RESULTS: The day-28 genotype-adjusted adequate clinical and parasitological response rate in 308 patients studied was > 97% by both intention-to-treat and per-protocol analysis. After excluding 64 patients with quantifiable amodiaquine concentrations pre-treatment and 17 with too few quantifiable concentrations, the pharmacokinetic analysis included 227 patients (9 infants, 127 aged 1-4 years, 91 aged ≥ 5 years). Increased median day-3 amodiaquine concentrations were associated with a lower risk of treatment failure [HR 0.87 (95% CI 0.78-0.98), p = 0.021]. Amodiaquine exposure (median AUC0-∞) was significantly higher in infants (4201 ng h/mL) and children aged 1-5 years (1994 ng h/mL) compared to older children and adults (875 ng h/mL, p = 0.001), even though infants received a lower mg/kg amodiaquine dose (median 25.3 versus 33.8 mg/kg in older patients). Desethylamodiaquine AUC0-∞ was not significantly associated with age. No significant safety concerns were identified. CONCLUSIONS: Efficacy of artesunate-amodiaquine at currently recommended dosage regimens was high across all age groups. Reassuringly, amodiaquine and desethylamodiaquine exposure was not reduced in underweight-for-age young children or those with high parasitaemia, two of the most vulnerable target populations. A larger pharmacokinetic study with close monitoring of safety, including full blood counts and liver function tests, is needed to confirm the higher amodiaquine exposure in infants, understand any safety implications and assess whether dose optimization in this vulnerable, understudied population is needed.
Entities:
Keywords:
Amodiaquine; Artesunate; Fixed-dose combination; Ghana; Infants; P. falciparum malaria; Parasite density; Pharmacokinetics; Underweight-for-age; Young children
Authors: Benjamin K Abuaku; Benedicta A Mensah; Michael F Ofori; James Myers-Hansen; Abigail N Derkyi-Kwarteng; Felicia Essilfie; Moses Dokurugu; Emmanuel Amoakoh; Kwadwo A Koram; Anita Ghansah Journal: Am J Trop Med Hyg Date: 2017-07-27 Impact factor: 2.345
Authors: A R Oduro; T Anyorigiya; F Anto; L Amenga-Etego; N A Ansah; P Atobrah; P Ansah; K Koram; A Hodgson Journal: Ann Trop Med Parasitol Date: 2008-10
Authors: Julie A Simpson; Kris M Jamsen; Ric N Price; Nicholas J White; Niklas Lindegardh; Joel Tarning; Stephen B Duffull Journal: Malar J Date: 2009-08-06 Impact factor: 2.979
Authors: George O Adjei; Jorgen A L Kurtzhals; Onike P Rodrigues; Michael Alifrangis; Lotte C G Hoegberg; Emmanuel D Kitcher; Ebenezer V Badoe; Roberta Lamptey; Bamenla Q Goka Journal: Malar J Date: 2008-07-11 Impact factor: 2.979
Authors: Seth Owusu-Agyei; Kwaku Poku Asante; Ruth Owusu; Martin Adjuik; Stephen Amenga-Etego; David Kwame Dosoo; John Gyapong; Brian Greenwood; Daniel Chandramohan Journal: PLoS One Date: 2008-06-25 Impact factor: 3.240
Authors: Thomas A Anyorigiya; Sandra Castel; Katya Mauf; Frank Atuguba; Bernhards Ogutu; Abraham Oduro; David Dosoo; Kwaku-Poku Asante; Seth Owusu-Agyei; Alexander Dodoo; Abraham Hodgson; Fred Binka; Lesley J Workman; Elizabeth N Allen; Paolo Denti; Lubbe Wiesner; Karen I Barnes Journal: Malar J Date: 2021-03-19 Impact factor: 2.979